Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

31. Januar 2025 11:18 ET | Quelle: Truveta

New Truveta study highlights patterns of discontinuation and reinitiation of GLP-1 RA medications

BELLEVUE, Wash., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has...
08. Juli 2024 11:16 ET | Quelle: Truveta

Truveta’s real-world data study comparing tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss published in JAMA Internal Medicine

BELLEVUE, Wash., July 08, 2024 (GLOBE NEWSWIRE) -- Today Truveta announced that its comparative effectiveness study exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide...
27. November 2023 09:00 ET | Quelle: Truveta

Largest real-world study finds tirzepatide (Mounjaro) up to three times more effective than semaglutide (Ozempic) for weight loss

BELLEVUE, Wash., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Today Truveta announced new comparative effectiveness research exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide...